Connect
← Return to Adding a second medicine question
Discussion
Adding a second medicine question
Prostate Cancer | Last Active: Jul 19 9:28pm | Replies (37)Comment receiving replies
T1cN1M0 is a staging designation used in cancer, specifically for non-small cell lung cancer and breast cancer. Not prostate cancer.
This doesn’t correlate with what you are saying about prostate cancer.
Individual Lymph nodes frequently have prostate cancer, not unusual and yes Oligometastic means that you actually have metastasis. You are metastatic, so you can get Nubeqa.
Unless you have some other type of cancer as well.
Replies to "T1cN1M0 is a staging designation used in cancer, specifically for non-small cell lung cancer and breast..."
Connect
I don’t know. NCCN guidelines use this for prostate cancer staging as does the American Cancer Society. You can have N1 - nodal involvement but still be M0 - no distant metastasis. So while not strictly non metastatic this is no longer necessarily considered metastatic but may be considered localized or I believe termed oligometastaic and treated with curative intent.
Anyway no matter the terminology my question is does anyone have experience with the effects of stopping ADT + Nubeqa or any of the second or first generation ARSIs? A lot of ARSIs are prescribed indefinitely or until they stop working. So I was interested in any experience with dropping off the ARSIs and ADT with curative intent.
Also it’s normally ADT + Abiraterone that is used during radiation. I don’t believe there are studies completed that show that the addition of ARSI to ADT and radiation are of benefit above ADT and radiation for new patients. Or for which patients in which risk level it may be beneficial. A lot of this exists for abiraterone but not for ARSIs.